The starting material of 5-fluorouracil-1-acetic acid was prepared from 5-fluorouracil and bromoacetic acid following the method of the literature [1] . The key intermediate methyl 2-(5-fluorouracil-1-aceto)amino acetate was synthesized from 5-fluorouracil-1-acetic acid, dicyclohexyl carbodiimide (dcc), and 1-hydroxybenzotriazole (btOH). An N,N-dimethylformamide (dmf) solution (25 ml) of dcc (0.024 mol, 4.94 g) was dropped in a dmf solution (75 ml) of 5-fluorouracil-1-acetic acid (0.02 mol, 3.76 g) and btOH (0.02 mol, 2.70 g) at 273 K. After 5 h reaction at room temperature, methyl glycinate (0.02 mol, 2.51 g) and triethylamine (0.02 mol, 2.02 g) were added to the above mixture. After 4 h reaction, a white solid methyl 2-(5-fluorouracil-1-aceto) amino acetate was obtained after filtration, reduced pressure distillation of dmf, and column chromatography separation. The title compound was obtained by hydrolysis with 1 M sodium hydroxide solution. The purified product was dissolved in 95 % ethanol and single crystals were separated after 10 days. Mass, IR, 1 H NMR and
H NMR and

13
C NMR data are available in the CIF. Discussion 5-Fluorouracil (5FU) is one of the antitumor agents most frequently used for treating solid tumors, such as breast, colorectal, and gastric cancers, in either monotherapy or combination therapy with various cytotoxic drugs [2, 3] . However, because of its poorly tumor selective and high incidences of toxicity in the bone marrow, gastrointestinal tract, central nervous system and skin, many derivatives of 5FU have been developed to improve its topical delivery and reduce the side effects [4] [5] [6] . In an extension of this research, we synthesized the title compound, a dipeptide derivative of 5FU, 2-(5-fluorouracil-1-aceto) amino acetic acid, and determined its crystal structure. 
